Human Genome reiterated at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Human Genome Sciences, Inc. at market outperform on news the U.S. Health and Human Sciences department purchased 20,000 doses of ABthrax, an antibody therapeutic against inhaled anthrax infection. The contract awarded to Human Genome, worth $165 million, is a significant milestone in the company's transformation to a commercial-stage company, according to the analyst. Shares of the Rockville, Md.-based biopharmaceutical company were up 17 cents, or 1.71%, at $10.13 on volume of 2,848,754 shares versus the three-month running average of 3,211,450 shares. (Nasdaq: HGSI)

Merrill puts Human Genome at buy

Human Genome Sciences, Inc. was rated at buy by Merrill Lynch analyst Hari Sambasivam. The company expects to receive 90% of the ABthrax revenue from the U.S. government in 2008. The remaining 10% is payable upon Food and Drug Administration approval. In addition, Human Genome will disclose data relating to the LymphoStat-B at the upcoming 2006 EULAR meeting. Shares of the Rockville, Md.-based biopharmaceutical company were up 17 cents, or 1.71%, at $10.13 on volume of 2,848,754 shares versus the three-month running average of 3,211,450 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.